Avantor® Reports Third Quarter 2026 Results
Avantor returned to year-over-year growth in Q3 2026 with net sales of $1,698.3 million, up 4.6% reported and 5.2% organically, exceeding management's expectations for revenue and adjusted EPS. GAAP diluted EPS was $0.30 on net income of $203.4 million, while adjusted EPS was $0.22, flat with the prior year. Free cash flow was $156.2 million, and adjusted net leverage improved to 3.1x as the company strengthened its balance sheet. FY26 guidance was raised: organic revenue growth to +0.75% to +1.25%, adjusted EPS to $0.81-$0.83, and free cash flow to $525M-$550M.
Key figures
- Eps
- 0.3
- Revenue
- 1698300000
- Guidance
- FY26 organic revenue growth raised to +0.75% to +1.25% (from -0.5% to +0.5%); adjusted EPS $0.81-$0.83 (from $0.80-$0.83); free cash flow $525M-$550M (from $500M-$550M)
- Revenue Yoy
- 4.6%
- Fcf
- 156200000
- Cash
- 464300000
- Gross debt
- 3699700000
- Net income
- 203400000
- Adjusted eps
- 0.22
- Adjusted ebitda
- 256900000
- Operating income
- 139500000
- Gaap net leverage
- 9.6x
- Vwr organic growth
- 5.8%
- Adjusted net income
- 146400000
- Operating cash flow
- 195100000
- Adjusted net leverage
- 3.1x
- Adjusted ebitda margin
- 15.1%
- Organic revenue growth
- 5.2%
- Adjusted operating income
- 227600000
- Bioscience organic growth
- 3.6%
- Bioscience segment revenue
- 464500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.